Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10428194.2024.2381647 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
At-Home Care Program for Acute Myeloid Leukemia Induction Phase in Patients Treated with Venetoclax-Based Low-Intensity Regimens.
Cancers (Basel)
December 2024
Department of Hematology, Hospital Clínic Barcelona, 08036 Barcelona, Spain.
Even though venetoclax in combination with azacitidine (VenAza) is considered a low-intensity regimen, its patients present a high incidence of cytopenia and infections during the first courses, making the initial management a challenging phase. This difficulty in our center led to the establishment of an At-Home (AH) program for ramp-up and follow-up patients during the VenAza combination induction phase focused on therapy administration, patient and caregiver education, and management of adverse events (AEs). A total of 70 patients with newly diagnosed acute myeloid leukemia (ND-AML) or relapsed/refractory AML (R/R AML) were treated with VenAza from March 2019 to May 2022.
View Article and Find Full Text PDFBackground: Patients with secondary acute myeloid leukemia who previously received hypomethylating agents for prior myeloid neoplasms (HMA-sAML) face a dismal prognosis.
Methods: The authors analyze the characteristics, therapeutic approaches, and outcomes of patients with HMA-sAML from the Programa Español para el Tratamiento de Hemopatías Malignas (PETHEMA) registry.
Results: A total of 479 patients were included, mostly from prior myelodysplastic syndrome (84%).
Significance of cycle 1 bone marrow biopsy in predicting outcomes and toxicities of venetoclax-based therapy for myeloid malignancies.
Leuk Lymphoma
December 2024
Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.
For older unfit patients receiving venetoclax-based induction, data on the significance of interim bone marrow biopies (BMBx) findings on clinical outcomes is lacking. We retrospectively evaluated interim BMBx results performed on Cycle 1 days 21-28 of venetoclax-based therapy in 69 adults with myeloid malignancies to determine whether blast clearance was associated with overall survival (OS) and overall response rate (ORR). Median age was 75 years (range 69-78).
View Article and Find Full Text PDFStrategies for the prophylaxis of invasive fungal diseases in acute myeloid leukemia patients undergoing Bcl-2 inhibitor venetoclax treatment.
J Infect Chemother
February 2025
Department of Hematology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China. Electronic address:
Patients with acute myeloid leukemia (AML) are at high risk of developing invasive fungal disease (IFD) with high morbidity and attributable mortality, including those who were received Venetoclax treatment. Venetoclax, a new oral Bcl-2 inhibitor, targets tumor cells' ability to induce apoptosis. It is the only one which is approved by Food and Drug Administration (FDA) for treating newly diagnosed AML patients who are 75 years of age or older and are ineligible for intensive induction chemotherapy due to existing comorbidities.
View Article and Find Full Text PDFAcute Myeloid Leukemia in Older Patients: From New Biological Insights to Targeted Therapies.
Curr Oncol
October 2024
Hematology Unit, S. Eugenio Hospital (ASL Roma 2), 00144 Rome, Italy.
Article Synopsis
- Acute myeloid leukemia (AML) is a complex type of blood cancer mainly affecting older adults, who often have poor outcomes due to their overall health and other medical issues.
- Recent studies have uncovered important molecular and biological factors related to AML, leading to improved treatment options for older patients.
- The article reviews the latest advancements in understanding and treating AML, focusing on how these developments are changing care for older adults with the disease.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!